Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study.

[1]  M. Jeffery,et al.  Follow-up strategies for patients treated for non-metastatic colorectal cancer. , 2016, The Cochrane database of systematic reviews.

[2]  M. Mazumdar,et al.  Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer , 2005, Annals of surgery.

[3]  C. Ko,et al.  Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.

[4]  Katherine S. Virgo,et al.  Follow-up of colorectal cancer patients after resection with curative intent-the GILDA trial. , 2004, Surgical oncology.

[5]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[6]  David K Whynes,et al.  Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer , 2004, BMJ : British Medical Journal.

[7]  C. Earle,et al.  Follow-up of patients with curatively resected colorectal cancer: a practice guideline , 2003, BMC Cancer.

[8]  M. Yasutomi,et al.  Changes in Colorectal Cancer During a 20-Year Period: An Extended Report From the Multi-Institutional Registry of Large Bowel Cancer, Japan , 2003, Diseases of the colon and rectum.

[9]  G. Ravera,et al.  Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  M. Egger,et al.  Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials , 2002, BMJ : British Medical Journal.

[11]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[12]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[14]  O. Bouché,et al.  Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Costi,et al.  Role of follow-up in management of local recurrences of colorectal cancer , 1998, Diseases of the colon and rectum.

[16]  O. Kronborg,et al.  A prospective randomized study of follow‐up after radical surgery for colorectal cancer , 1997, The British journal of surgery.

[17]  M. Kairaluoma,et al.  Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. , 1995, Archives of surgery.

[18]  H. Graffner,et al.  Follow-up after curative surgery for colorectal carcinoma , 1995, Diseases of the colon and rectum.

[19]  E. Grundmann,et al.  Haematogenous metastastic patterns in colonic carcinoma: An analysis of 1541 necropsies , 1986 .

[20]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[21]  J. Toouli,et al.  Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. , 1998, Gastroenterology.